Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Hongshu, Ma, Ningxia, Wang, Ying, Li, Hui, Liu, Xiaoming, Su, Yanping, Yang, Jiali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109480/
https://www.ncbi.nlm.nih.gov/pubmed/30159341
http://dx.doi.org/10.1155/2018/6984948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109480/
https://www.ncbi.nlm.nih.gov/pubmed/30159341
http://dx.doi.org/10.1155/2018/6984948

Ejemplares similares